logo

CNMD

CONMED·NYSE
--
--(--)
--
--(--)
4.64 / 10
Netural

Financial analysis yields a balanced rating (4.6/10). Key positives include strong Profit-MV (0.51) and Cash-MV (0.13) factors, indicating robust earnings and cash relative to market value. However, Net income-Revenue is negative (-1.20), and several ratios like ROA (%) and Annualized net profit margin fall in lower-performing quartiles. Asset-MV is also negative (-0.51), suggesting higher asset base than peers. Overall, fundamentals are mixed with both strengths and weaknesses.

Fundamental(4.64)SentimentTechnical

Analysis Checks(10/10)

Revenue-MV
Value0.21
Score2/3
Weight-2.50%
1M Return-0.16%
ROA (%)
Value1.31
Score2/3
Weight-4.28%
1M Return-0.25%
Net cash flow from operating activities / Operating revenue (%)
Value12.42
Score3/3
Weight18.65%
1M Return1.03%
Profit-MV
Value0.51
Score2/3
Weight54.42%
1M Return2.92%
Net income-Revenue
Value-1.20
Score2/3
Weight-33.90%
1M Return-2.32%
Cash-UP
Value0.06
Score2/3
Weight-59.67%
1M Return-4.39%
Annualized net profit margin on total assets (%)
Value1.75
Score2/3
Weight-4.28%
1M Return-0.25%
Asset-MV
Value-0.51
Score2/3
Weight24.24%
1M Return1.35%
Cash-MV
Value0.13
Score2/3
Weight94.13%
1M Return4.51%
Net profit / Total profit (%)
Value72.42
Score3/3
Weight13.18%
1M Return0.77%
Is CNMD undervalued or overvalued?
  • CNMD scores 4.64/10 on fundamentals and holds a Fair valuation at present. Backed by its 3.08% ROE, 4.75% net margin, 20.07 P/E ratio, 1.28 P/B ratio, and -51.64% earnings growth, these metrics solidify its Netural investment rating.